Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists (Q34910366)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists (English)

1 reference

Europe PubMed Central

5 August 2017

0 references

1 reference

based on heuristic

inferred from title

Michael J Rybak

1

object named as

Michael Rybak

1 reference

Europe PubMed Central

5 August 2017

Joseph R. Dalovisio

7

object named as

Joseph R Dalovisio

1 reference

Europe PubMed Central

5 August 2017

author name string

Ben Lomaestro

2

1 reference

Europe PubMed Central

5 August 2017

John C Rotschafer

3

1 reference

Europe PubMed Central

5 August 2017

Robert Moellering

4

1 reference

Europe PubMed Central

5 August 2017

William Craig

5

1 reference

Europe PubMed Central

5 August 2017

Marianne Billeter

6

1 reference

Europe PubMed Central

5 August 2017

Donald P Levine

8

1 reference

Europe PubMed Central

5 August 2017

publication date

1 January 2009

1 reference

Europe PubMed Central

5 August 2017

American Journal of Health-System Pharmacy

1 reference

Europe PubMed Central

5 August 2017

66

1 reference

Europe PubMed Central

5 August 2017

1

1 reference

Europe PubMed Central

5 August 2017

82-98

1 reference

Europe PubMed Central

5 August 2017

Vancomycin: a 50-year reassessment

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin: a history

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

The role of vancomycin in the treatment paradigm

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

The pharmacokinetic and pharmacodynamic properties of vancomycin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Mississippi mud no more: cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Serum Vancomycin Concentrations: Reappraisal of Their Clinical Value

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Monitoring serum vancomycin levels: climbing the mountain because it is there?

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Nephrotoxicity of vancomycin, alone and with an aminoglycoside

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin pharmacokinetics in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Pharmacokinetics of vancomycin in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin pharmacokinetics in normal and morbidly obese subjects

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin serum protein binding determination by ultrafiltration.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin protein binding in patients with infections caused by Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Penetration of vancomycin into human lung tissue

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Pulmonary disposition of vancomycin in critically ill patients.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Pharmacodynamics: relation to antimicrobial resistance

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Outcome assessment of minimizing vancomycin monitoring and dosing adjustments

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Staphylococcus aureus with reduced susceptibility to vancomycin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Autoinduction and signal transduction in the regulation of staphylococcal virulence

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Necessity of a loading dose when using vancomycin in critically ill patients

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Symposium on antimicrobial agents--Part XII. Vancomycin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin-induced neutropenia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin toxicity: a prospective study

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

A prospective study of adverse reactions associated with vancomycin therapy

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Aminoglycoside and glycopeptide renal toxicity in intensive care patients studied by proton magnetic resonance spectroscopy of urine

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells in the rat.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Cost-ineffectiveness of serum vancomycin levels

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Effects of vancomycin on renal function in rats

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin enhancement of experimental tobramycin nephrotoxicity

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Renal tolerance and pharmacokinetics of vancomycin in rats

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Chrononephrotoxicity in rat of a vancomycin and gentamicin combination

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Influence of fosfomycin and tobramycin on vancomycin-induced nephrotoxicity

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Gentamicin-induced renal metabolic alterations in newborn rat kidney: lack of potentiation by vancomycin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Lack of nephrotoxicity in pediatric patients receiving concurrent vancomycin and aminoglycoside therapy

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Impact of vancomycin therapeutic drug monitoring on patient care

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

The Ototoxic Interaction of Viomycin, Capreomycin and Polymyxin B With Ethacrynic Acid

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

An experimental study of vancomycin-induced cochlear damage.

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin Ototoxicity in a Patient with Normal Renal Function

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Vancomycin- and erythromycin-induced hearing loss in humans

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Treatment of staphylococcal septicemia with vancomycin: report of thirty-three cases

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Why monitor peak vancomycin concentrations?

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Early vancomycin therapy and adverse outcomes in children with pneumococcal meningitis

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080434

31 March 2020

Identifiers

10.2146/AJHP080434

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34910366&oldid=2068998603"